| Literature DB >> 33708925 |
Zhenyuan Ning1,2, Jiaxiu Luo1,2, Qing Xiao1,2, Longmei Cai3, Yuting Chen3, Xiaohui Yu1,2, Jian Wang1,2,3, Yu Zhang1,2.
Abstract
BACKGROUND: To investigate the feasibility of integrating global radiomics and local deep features based on multi-modal magnetic resonance imaging (MRI) for developing a noninvasive glioma grading model.Entities:
Keywords: Glioma grading; artificial intelligence (AI); deep learning; integrative analysis; radiomics
Year: 2021 PMID: 33708925 PMCID: PMC7944310 DOI: 10.21037/atm-20-4076
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1The flowchart of the proposed integrative framework. It included four steps, namely, (A) tumor imaging and segmentation, (B) radiomics feature extraction, (C) deep feature extraction, and (D) kernel fusion-based multi-modal analysis.
Clinical characteristics of patients on the TCIA cohort and independent testing cohort
| Characteristic | TCIA cohort | Independent testing cohort | |||||
|---|---|---|---|---|---|---|---|
| GBM | LGG | P value | GBM | LGG | P value | ||
| Patients | 106/233 (45.5) | 127/233(54.5) | 105/334 (31.4) | 229/334 (68.6) | |||
| Age (year) | 58.7±13.6 | 46.0±13.8 | <0.001* | 44.3±13.3 | 37.5±11.6 | <0.001* | |
| Gender | 0.04* | <0.001* | |||||
| Woman | 41/106 (38.7) | 63/127 (49.6) | 35/105 (33.3) | 107/229 (46.7) | |||
| Man | 65/106 (61.3) | 64/127 (50.4) | 70/105 (66.7) | 122/229 (53.3) | |||
| Tumor grade | <0.001* | <0.001* | |||||
| WHO II | 0 (0.0) | 63 (49.6) | 0 (0.0) | 112 (48.9) | |||
| WHO III | 0 (0.0) | 64 (50.4) | 0 (0.0) | 117 (51.1) | |||
| WHO IV | 106 (100.0) | 0 (0.0) | 105 (100.0) | 0 (0.0) | |||
| 1p19q codeletion | <0.001* | 0.70 | |||||
| Codeletion | 0/106 (0.0) | 36/127 (28.3) | 5/105 (4.8) | 14/229 (6.1) | |||
| Wild type | 106/106 (100.0) | 91/127 (71.7) | 12/105 (11.4) | 31/229 (13.5) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 88/105 (83.8) | 184/229 (80.4) | |||
| IDH mutation | 0.64 | <0.001* | |||||
| Mutation | 8/106 (7.5) | 103/127 (81.1) | 18/105 (17.1) | 110/229 (48.0) | |||
| Wild type | 98/106 (92.5) | 24/127 (18.9) | 46/105 (43.8) | 48/229 (21.0) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 41/105 (39.1) | 71/229 (31.0) | |||
| Histology | <0.001* | <0.001* | |||||
| Astrocytoma | 0/106 (0.0) | 36/127 (28.3) | 0/105 (0.0) | 82/229 (35.8) | |||
| Oligoastrocytoma | 0/106 (0.0) | 32/127 (25.2) | 0/105 (0.0) | 83/229 (36.2) | |||
| Oligodendroglioma | 0/106 (0.0) | 59/127 (46.5) | 0/105 (0.0) | 44/229 (19.2) | |||
| Glioblastoma | 106/106 (100.0) | 0/127 (0.0) | 105/105 (100.0) | 0/229 (0.0) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 0/105 (0.0) | 20/229 (8.8) | |||
Data in parentheses are percentages. * indicates significant difference.
Figure 2Patient inclusion and exclusion criteria on internal validation cohort and external testing cohort.
Figure 3Average AUC of models on internal validation cohort with different feature dimensions from 1 to 30. The k=19 achieved the best performance with AUC of 0.86.
Comparison of the proposed method with the models based on different methodologies and modalities
| Method | Validation AUC | Sensitivity (%) | Specificity (%) | Testing AUC | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|
| R_T2 FLAIR | 0.88 (0.75, 0.95) | 76 (16/21) | 85 (22/26) | 0.81 (0.77, 0.85) | 80 (84/105) | 71 (163/229) |
| R_T1ce | 0.87 (0.74, 0.95) | 81 (17/21) | 77 (20/26) | 0.80 (0.75, 0.84) | 71 (75/105) | 79 (180/229) |
| R_T2 FLAIR + T1ce | 0.92 (0.80, 0.98) | 86 (18/21) | 85 (22/26) | 0.85 (0.81, 0.89) | 85 (89/105) | 76 (175/229) |
| D_T2 FLAIR | 0.86 (0.73, 0.95) | 81 (17/21) | 77 (20/26) | 0.79 (0.75, 0.84) | 75 (79/105) | 76 (175/229) |
| D_T1ce | 0.88 (0.75, 0.95) | 71 (15/21) | 88 (23/26) | 0.80 (0.76, 0.84) | 80 (84/105) | 69 (158/229) |
| D_T2 FLAIR + T1ce | 0.91 (0.79, 0.97) | 81 (17/21) | 88 (23/26) | 0.84 (0.80, 0.88) | 82 (86/105) | 77 (176/229) |
| R + D_ T2 FLAIR | 0.90 (0.77, 0.97) | 81 (17/21) | 85 (22/26) | 0.82 (0.78, 0.86) | 78 (82/105) | 76 (173/229) |
| R + D_T1ce | 0.90 (0.80, 0.98) | 86 (18/21) | 81 (21/26) | 0.82 (0.77, 0.86) | 81 (85/105) | 75 (172/229) |
| Proposed method | 0.94 (0.85, 0.99) | 86 (18/21) | 92 (24/26) | 0.88 (0.85, 0.92) | 88 (92/105) | 81 (186/229) |
Note. R_: Radiomics, D_: Deep learning, R + D_: Radiomics + Deep learning
Performance of models using different feature selection methods and classifiers
| Method | Validation AUC | Sensitivity (%) | Specificity (%) | Testing AUC | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|
| mRMR + SVM | 0.92 (0.80, 0.98) | 86 (18/21) | 85 (22/26) | 0.85 (0.81, 0.89) | 87 (91/105) | 74 (169/229) |
| FF + SVM | 0.90 (0.77, 0.97) | 86 (18/21) | 88 (23/26) | 0.84 (0.80, 0.88) | 83 (87/105) | 75 (171/229) |
| Relief + RF | 0.92 (0.80, 0.98) | 81 (17/21) | 92 (24/26) | 0.86 (0.82, 0.90) | 85 (89/105) | 81 (186/229) |
| Relief + SVM | 0.94 (0.85, 0.99) | 86 (18/21) | 92 (24/26) | 0.88 (0.84, 0.91) | 88 (92/105) | 81 (186/229) |
Comparison between three radiologists and the proposed method for gliomas grading
| Radiologist | Validation cohort | Testing cohort | |||
|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) | ||
| Reader 1 | 90 (19/21) | 77 (20/26) | 84 (88/105) | 75 (172/229) | |
| Reader 2 | 86 (18/21) | 85 (22/26) | 81 (85/105) | 78 (178/229) | |
| Reader 3 | 86 (18/21) | 73 (19/26) | 80 (84/105) | 72 (165/229) | |
| Proposed method | 86 (18/21) | 92 (24/26) | 88 (92/105) | 81 (186/229) | |
Figure 4ROC curve of the proposed method on internal validation cohort (A) and external testing cohort (B). Three points representing sensitivity and specificity of three readers were plotted.